Listed on the Stock Exchange of Hong Kong in June 2007, TUL is one of the leading comprehensive pharmaceutical companies in China, principally engaged in the R&D, manufacturing and selling of finished products, bulk medicines and intermediate products. The Group has six production bases, and its production and sales teams for intermediate products, bulk medicines and finished products formed a broad sales network covering China and the rest of the world. As a domestic pharmaceutical company with both second-generation and third-generation insulin products in China, the Group's recombinant human insulin injection, insulin glargine injection and insulin aspart injection products have all been approved for marketing. TUL is now one of the constituent stocks of The Hang Seng Composite Index Series.
updated 12th May, 2022
|© Copyright 1996-2022 irasia.com Ltd. All rights reserved.|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited.